Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Biochaperone insulin lispro 0.1 U/kg · 1 trial · 1 indication
Area under the insulin lispro serum concentration - time curve from t=0 to 30 minutes
| Arm | Type | Description |
|---|---|---|
| BioChaperone insulin lispro 0.1 U/kg | EXPERIMENTAL | - |
| BioChaperone insulin lispro 0.2 U/kg | EXPERIMENTAL | - |
| BioChaperone insulin lispro 0.4 U/kg | EXPERIMENTAL | - |
| Humalog® | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Biochaperone insulin lispro 0.1 U/kg | DRUG | Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg |
| Biochaperone insulin lispro 0.2 U/kg | DRUG | Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg |
| Biochaperone insulin lispro 0.4 U/kg | DRUG | Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg |
| Humalog® | DRUG | Injection of a single dose of Humalog® at the dose of 0.2 U/kg |
Inclusion Criteria: * Healthy Japanese male or female subjects by completion of medical history, physical examination and biochemical investigations as judged by the Investigator. * BMI between 18.5 and 25.0 kg∙m-2, both inclusive. * Fasting Plasma Glucose ≤ 5.6 mmol/L (100 mg/dL). * Signed and dat...
Biochaperone insulin lispro 0.1 U/kg is an investigational small molecule being studied in healthy volunteers. It is being evaluated in a Phase 1 clinical trial to assess its pharmacokinetics. The drug is not approved for any indication and is still in clinical development.
Biochaperone insulin lispro 0.1 U/kg is being developed by Eli Lilly and Company, which trades under the ticker LLY. The company is conducting clinical trials to evaluate the drug's pharmacokinetics in healthy subjects.
Biochaperone insulin lispro 0.1 U/kg is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed.
Biochaperone insulin lispro 0.1 U/kg has one completed clinical trial, NCT02660502, titled "An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects." The trial enrolled 15 participants in Germany.
Biochaperone insulin lispro 0.1 U/kg is a formulation of insulin lispro combined with a biochaperone technology. It is being studied for its pharmacokinetic profile in healthy subjects. The drug is distinct from standard insulin lispro due to this biochaperone component.